<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20171031037130N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-05-07</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>The effects of Oxytocin on Ovulation and Pregnancy</public_title>
      <acronym></acronym>
      <scientific_title>The effects of oxytocin and human chorionic gonadotropin in clomiphene citrate resistant  polycystic ovary syndrome patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-10-25</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>126</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/27549</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, after determining the sample size, Patients were randomly assigned to one of three groups using stratified randomization. Allocation Concealment was performed by sealed envelopes, Blinding description: In this study, a plan was first described for the patient.The patient, the researcher and the physician did not know the group. For each treatment, the code was assigned and placed in an  envelop and then put in a box, randomly.The agent who conducted the randomization process, did not engage with other steps.</study_design>
      <phase>2</phase>
      <hc_freetext>Polycystic ovarian syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Letrozole (5 mg) was given since second to the fifth day of the menstrual cycle for 5 days, to grow follicles. Then, trans vaginal ultrasonography was performed on thirteenth day of menstrual cycle to measure the dominant follicle size, follicular count and endometrial thickness. In women with a follicle of 18 to 22 mm, to stimulate ovulation, 10-unit of oxytocin  were injected. Then participants were examined for pregnancy (biochemical or clinical) and abortion and multiple pregnancies. Intervention 2: Intervention group 2: Letrozole (5 mg) was given since second to the fifth day of the menstrual cycle for 5 days, to grow follicles. Then, transvaginal ultrasonography was performed on thirteenth day of menstrual cycle to measure the dominant follicle size, follicular count and endometrial thickness. In women with a follicle of 18 to 22 mm, to stimulate ovulation, 5,000-unit HCG were injected. Then participants were examined for pregnancy (biochemical or clinical) and abortion and multiple pregnancies. Intervention 3: Intervention group 3: Letrozole (5 mg) was given since second to the fifth day of the menstrual cycle for 5 days, to grow follicles. Then, transvaginal ultrasonography was performed on thirteenth day of menstrual cycle to measure the dominant follicle size, follicular count and endometrial thickness. In women with a follicle of 18 to 22 mm, to stimulate ovulation, 10-unit of oxytocin and 5,000-unit HCG were injected. Then participants were examined for pregnancy (biochemical or clinical) and abortion and multiple pregnancies.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mojgan Javedani Masroor</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Akbar abadi hospital, Molavi intersectino, Molavi Ave,</address>
        <city>tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1168743514</zip>
        <telephone>+98 21 5560 6034</telephone>
        <email>javedanimasroor.m@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mojgan Javedani Masroor</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Akbar abadi hospital, Molavi intersectino, Molavi Ave,</address>
        <city>tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1168743514</zip>
        <telephone>+98 21 5560 6034</telephone>
        <email>javedanimasroor.m@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Clomiphen citrate resistant poly cystic ovary syndrome patients
19 - 45 years old
At least one ovarian tube is open in HSG
Normal Semen analysis of husband
No other pelvic pathology</inclusion_criteria>
      <agemin>19 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Hypersensitivity to Oxytocin
History of Cardio vascular disease
Use of anti hypertensive drug
blood pressure lower than 60/90
abnormal spermogram
hyper prolactinoma
anatomical disorder of uterus and tubal factor
karyotype disorder</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E28.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Polycystic ovarian syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Letrozole (5 mg) was given since second to the fifth day of the menstrual cycle for 5 days, to grow follicles. Then, trans vaginal ultrasonography was performed on thirteenth day of menstrual cycle to measure the dominant follicle size, follicular count and endometrial thickness. In women with a follicle of 18 to 22 mm, to stimulate ovulation, 10-unit of oxytocin  were injected. Then participants were examined for pregnancy (biochemical or clinical) and abortion and multiple pregnancies</i_keyword>
      <i_keyword>Intervention group 2: Letrozole (5 mg) was given since second to the fifth day of the menstrual cycle for 5 days, to grow follicles. Then, transvaginal ultrasonography was performed on thirteenth day of menstrual cycle to measure the dominant follicle size, follicular count and endometrial thickness. In women with a follicle of 18 to 22 mm, to stimulate ovulation, 5,000-unit HCG were injected. Then participants were examined for pregnancy (biochemical or clinical) and abortion and multiple pregnancies</i_keyword>
      <i_keyword>Intervention group 3: Letrozole (5 mg) was given since second to the fifth day of the menstrual cycle for 5 days, to grow follicles. Then, transvaginal ultrasonography was performed on thirteenth day of menstrual cycle to measure the dominant follicle size, follicular count and endometrial thickness. In women with a follicle of 18 to 22 mm, to stimulate ovulation, 10-unit of oxytocin and 5,000-unit HCG were injected. Then participants were examined for pregnancy (biochemical or clinical) and abortion and multiple pregnancies</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pregnancy percentage. Timepoint: pregnancy test and sonography after induction of ovulation. Method of measurement: serum beta HCG.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-10-24</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences, Shahid Hemmat Highway, tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
